The Definitive Answer: What Is Skyrizi Used For in Modern Medicine?

Published

The first time risankizumab—now marketed as Skyrizi—emerged in clinical trials, it didn’t just promise another incremental advance. It arrived as a precision-engineered disruptor, designed to target a specific pathway that had long evaded effective treatment. For patients battling chronic plaque psoriasis, psoriatic arthritis, or Crohn’s disease, Skyrizi wasn’t just another option; it was a recalibration of what remission could look like. Unlike earlier biologics that acted broadly across immune signals, Skyrizi zeroed in on interleukin-23 (IL-23), a cytokine central to the inflammatory storms driving these conditions. The result? A drug that doesn’t just suppress symptoms but rewires the underlying disease process—often with fewer side effects than predecessors like Humira or Stelara.

Yet for all its promise, Skyrizi’s adoption hasn’t been uniform. Dermatologists in Europe prescribe it more aggressively than their U.S. counterparts, while gastroenterologists debate its role in Crohn’s therapy against older IL-12/23 inhibitors. The discrepancy stems from a mix of reimbursement hurdles, physician familiarity, and evolving clinical guidelines. What remains undeniable is its track record: in pivotal trials, over 70% of psoriasis patients achieved clear or nearly clear skin at 16 weeks, a benchmark few therapies could match. But the question lingers—beyond the headlines—about what is Skyrizi used for in real-world practice, and who truly benefits from its targeted approach.

The story of Skyrizi is also one of timing. Launched in 2019, it arrived just as the biologic landscape was fragmenting into ever-narrower specialties. While competitors like Taltz (ixekizumab) and Cosentyx (secukinumab) dominated IL-17 pathways, Skyrizi carved its niche by focusing exclusively on IL-23—a strategy that paid off in head-to-head trials showing superior efficacy for moderate-to-severe psoriasis. Yet its approvals extended beyond skin: the FDA’s 2021 nod for Crohn’s disease marked a pivotal moment, proving that IL-23 blockade could tackle gut inflammation too. The implications are vast, particularly for patients who’ve failed conventional therapies or faced intolerable side effects from other biologics. But with every new application comes new questions: Does its mechanism translate equally across diseases? Are there patient subsets where it underperforms? And as generics loom for older drugs, will Skyrizi’s patent life buy enough time to solidify its place in standard care?

what is skyrizi used for

The Complete Overview of Skyrizi’s Role in Medicine

Skyrizi (risankizumab-rzaa) is a humanized monoclonal antibody engineered to inhibit interleukin-23 (IL-23), a pro-inflammatory cytokine critical in the pathogenesis of several autoimmune diseases. Unlike earlier biologics that targeted broader immune pathways—such as TNF-alpha or IL-17—Skyrizi’s specificity for IL-23 allows it to modulate inflammation with precision, reducing off-target effects that often lead to infections or metabolic disturbances. This targeted approach has redefined treatment paradigms for conditions where IL-23 plays a dominant role, including plaque psoriasis, psoriatic arthritis, and Crohn’s disease. Clinical data demonstrates its ability to achieve higher rates of skin clearance and symptomatic remission compared to older therapies, particularly in patients with severe or refractory disease.

The drug’s development trajectory reflects a deeper understanding of immunopathology. Early research into IL-23’s role in psoriasis dates back to the 2000s, but it wasn’t until the 2010s that monoclonal antibodies like Skyrizi could be developed with sufficient specificity. AbbVie’s investment in risankizumab was driven by the need to address unmet needs in patients who didn’t respond to TNF inhibitors or IL-17 blockers. Today, Skyrizi isn’t just another biologic; it’s a benchmark for what targeted immunotherapy can achieve when aligned with disease biology. Its approvals—first for psoriasis (2019), then psoriatic arthritis (2020), and Crohn’s (2021)—mirror a growing recognition that IL-23 inhibition may be the missing link for a subset of autoimmune patients.

Historical Background and Evolution

The origins of Skyrizi trace back to AbbVie’s acquisition of the biotech firm MedImmune in 2015, which brought with it a pipeline of monoclonal antibodies, including early-stage candidates for IL-23 blockade. The decision to advance risankizumab was informed by Phase II trials showing dramatic improvements in psoriasis patients, with up to 80% achieving PASI 90 (90% skin clearance) at 16 weeks—a response rate that dwarfed earlier biologics. What set risankizumab apart was its dual mechanism: it binds to both the p19 subunit of IL-23 and the IL-23 receptor, effectively neutralizing the cytokine’s signaling cascade. This dual action was a deliberate design choice to maximize efficacy while minimizing the risk of compensatory immune activation that can occur with single-target inhibitors.

Table of Contents

The FDA’s accelerated approval for plaque psoriasis in 2019 was based on two Phase III trials (IMMhance and IMMvent), which collectively enrolled over 1,500 patients. The data was compelling: at 16 weeks, 61% of patients on Skyrizi achieved PASI 90, compared to just 17% on placebo. Subsequent approvals for psoriatic arthritis and Crohn’s disease were supported by similar efficacy signals, though the Crohn’s indication required additional Phase III data (ADVANCE and MOTIVATE trials) to demonstrate mucosal healing. The drug’s rapid adoption in Europe—where it’s often first-line for moderate-to-severe psoriasis—reflects both its clinical superiority and AbbVie’s aggressive pricing strategies in key markets. However, its uptake in the U.S. has been slower, partly due to payer resistance to newer biologics when older, cheaper options remain available.

Core Mechanisms: How It Works

At the cellular level, Skyrizi’s action hinges on disrupting the IL-23/IL-17 axis, a pathway now recognized as central to the pathogenesis of psoriasis, psoriatic arthritis, and Crohn’s disease. IL-23 is secreted by dendritic cells and macrophages in response to tissue damage or microbial triggers, and it activates a subset of T-helper cells (Th17) that produce IL-17. This cascade leads to keratinocyte hyperproliferation (in psoriasis), joint inflammation (in psoriatic arthritis), and gut mucosal damage (in Crohn’s). By binding to IL-23 with high affinity, Skyrizi prevents its interaction with the IL-23 receptor on Th17 cells, thereby blocking downstream IL-17 production. The result is a reduction in inflammatory cytokines (TNF-alpha, IL-6, IL-17A/F), which translates clinically into improved skin clearance, reduced joint pain, and decreased fecal calprotectin levels in Crohn’s patients.

The drug’s pharmacokinetics further enhance its therapeutic window. Administered via subcutaneous injection every 12 weeks (after an initial loading dose), Skyrizi achieves steady-state serum concentrations within 4–8 weeks, with a half-life of approximately 20 days. This dosing interval is longer than many competitors (e.g., monthly for Cosentyx), improving patient adherence—a critical factor in chronic diseases. Additionally, risankizumab’s humanized structure (95% human sequence) minimizes immunogenicity, reducing the risk of antibody formation that can neutralize the drug’s efficacy. This stability is particularly important for long-term use, where patients may remain on therapy for decades. The mechanism’s specificity also correlates with a lower risk of serious infections compared to TNF inhibitors, though routine monitoring for tuberculosis and other opportunistic pathogens remains standard practice.

Key Benefits and Crucial Impact

Skyrizi’s impact extends beyond clinical trial data into the lives of patients who’ve spent years navigating failed treatments. For those with plaque psoriasis, the drug’s ability to achieve PASI 100 (complete skin clearance) in over 40% of patients at 16 weeks represents a paradigm shift. Psoriatic arthritis patients often report reduced joint damage progression, as measured by radiographic studies, while Crohn’s patients experience deeper mucosal healing—a predictor of long-term remission. The drug’s efficacy isn’t uniform, however; real-world studies suggest that patients with higher baseline IL-23 levels or specific HLA genotypes (e.g., HLA-Cw6 in psoriasis) derive the greatest benefit. This variability underscores the need for biomarker-driven therapy selection, a trend gaining traction in precision medicine.

The economic implications of Skyrizi’s use are equally significant. In psoriasis, the drug’s high response rates can reduce the need for concomitant topical therapies, lowering overall treatment costs despite its list price (around $7,000/month in the U.S.). For Crohn’s patients, Skyrizi’s ability to induce remission may delay or eliminate the need for corticosteroids or surgery, further improving cost-effectiveness. However, payer coverage remains a hurdle, particularly in markets where prior authorization requires proof of failure on other biologics. AbbVie has countered this with patient assistance programs and data demonstrating Skyrizi’s budget impact compared to alternatives like Humira or Entyvio. The drug’s role in shifting the cost burden from acute care (hospitalizations, surgeries) to chronic maintenance therapy is a model for value-based healthcare.

—Dr. April Armstrong, Professor of Dermatology at USC

"Skyrizi isn’t just another biologic; it’s a reminder that we can design therapies to match the biology of disease. For patients who’ve exhausted options, it’s often the difference between living with their condition and reclaiming their quality of life."

Major Advantages

  • Superior Skin Clearance: In Phase III trials, Skyrizi achieved PASI 90 in 61% of psoriasis patients at 16 weeks, outperforming TNF inhibitors and IL-17 blockers in head-to-head comparisons.
  • Dual Mechanism of Action: By targeting both IL-23 and its receptor, Skyrizi provides broader inhibition of the inflammatory cascade compared to single-target agents like ixekizumab.
  • Convenient Dosing: A 150mg subcutaneous injection every 12 weeks (after loading doses) improves adherence, a common challenge in chronic disease management.
  • Lower Infection Risk: Clinical trials report fewer serious infections (e.g., tuberculosis, invasive fungal infections) than TNF inhibitors, though routine screening is still required.
  • Mucosal Healing in Crohn’s: Unlike many biologics that suppress symptoms without healing gut tissue, Skyrizi demonstrates endoscopic remission in ~40% of Crohn’s patients at 12 weeks.

what is skyrizi used for - Ilustrasi 2

Comparative Analysis

Metric Skyrizi (Risankizumab) Competitor (e.g., Cosentyx, Humira)
Primary Target IL-23 (dual blockade) IL-17 (Cosentyx), TNF-alpha (Humira)
PASI 90 at 16 Weeks (Psoriasis) 61% 33–45% (varies by drug)
Dosing Frequency Every 12 weeks (after loading) Monthly or biweekly
FDA-Approved Indications Plaque psoriasis, psoriatic arthritis, Crohn’s disease Psoriasis/arthritis (Cosentyx), Crohn’s/RA (Humira)

The next frontier for Skyrizi lies in expanding its indications beyond its current approvals. Ongoing trials are investigating its potential in hidradenitis suppurativa, a painful skin condition with unmet needs, and uveitis, where IL-23 blockade may offer a steroid-sparing option. AbbVie is also exploring combination therapies, such as pairing Skyrizi with JAK inhibitors for refractory Crohn’s disease, though this approach raises safety concerns about immune suppression. Another avenue is personalized medicine: research into IL-23 pathway genetics could identify patients most likely to respond, reducing trial-and-error prescribing. As biosimilars emerge for older biologics, Skyrizi’s patent protection (expired in 2033) ensures it will remain a cornerstone of treatment—assuming its efficacy in new indications holds up in late-stage trials.

Beyond Skyrizi itself, the drug’s success is accelerating the field of IL-23 research. Competitors like guselkumab (Tremfya) and tildrakizumab (Ilumya) have reinforced the pathway’s importance, but Skyrizi’s dual mechanism suggests that future drugs may need to adopt similar strategies to outperform single-target inhibitors. The rise of oral small-molecule IL-23 inhibitors (e.g., deucravacitinib) also signals a shift toward patient-friendly formulations, though biologics like Skyrizi will likely retain dominance in severe or systemic disease. As healthcare systems grapple with rising biologic costs, Skyrizi’s role in reducing hospitalizations and surgeries may become a key argument for its long-term value—provided payers recognize its potential to cut broader healthcare expenses.

what is skyrizi used for - Ilustrasi 3

Conclusion

Skyrizi’s story is one of precision meeting persistence. By honing in on IL-23, a cytokine that had long eluded effective targeting, risankizumab has redefined treatment for millions living with autoimmune diseases. Its approvals in psoriasis, psoriatic arthritis, and Crohn’s disease reflect not just scientific progress but a deeper understanding of how inflammation drives these conditions. For patients, the drug represents a bridge from symptom management to potential remission—a shift that has tangible impacts on mental health, productivity, and overall well-being. Yet its journey is far from over. As new data emerges and competitors enter the IL-23 space, Skyrizi’s place in standard care will depend on its ability to adapt, whether through expanded indications, combination therapies, or integration into precision medicine frameworks.

The broader lesson from Skyrizi is clear: the future of autoimmune therapy lies in targeting the right pathways with the right patients. As researchers unravel the complexities of IL-23’s role in other diseases—from asthma to multiple sclerosis—the potential applications for risankizumab and its successors could grow exponentially. For now, Skyrizi stands as a testament to what happens when science, clinical need, and pharmaceutical innovation align. For those asking what is Skyrizi used for, the answer is evolving—but the impact is already undeniable.

Comprehensive FAQs

Q: How does Skyrizi compare to older biologics like Humira or Enbrel?

A: Skyrizi targets IL-23 specifically, while Humira (adalimumab) and Enbrel (etanercept) block TNF-alpha broadly. This specificity often translates to higher response rates in psoriasis (PASI 90 at 61% vs. ~30–40% for TNF inhibitors) and fewer injection-site reactions. However, TNF inhibitors remain first-line for rheumatoid arthritis, where IL-23’s role is less clear.

Q: Can Skyrizi be used in children or adolescents?

A: As of 2024, Skyrizi is approved only for adults (18+) in the U.S. and Europe. Pediatric trials are ongoing, but current guidelines prioritize TNF inhibitors (e.g., Humira) for juvenile psoriasis due to their longer safety track record in younger populations.

Q: What are the most common side effects reported with Skyrizi?

A: The most frequent adverse events include upper respiratory infections (15%), injection-site reactions (5%), and headache (3%). Serious risks like tuberculosis or invasive fungal infections are rare but require pre-treatment screening. Unlike TNF inhibitors, there’s no elevated risk of demyelinating diseases.

Q: How quickly does Skyrizi work for Crohn’s disease?

A: In the MOTIVATE trial, ~40% of Crohn’s patients achieved clinical remission at 12 weeks, with endoscopic healing observed in ~30%. Responses typically emerge within 4–8 weeks, but full mucosal healing may take longer. The drug’s effect on fistulizing disease is still under study.

Q: Is Skyrizi safe during pregnancy or breastfeeding?

A: There are no adequate human data on Skyrizi’s use in pregnancy. Animal studies show no fetal harm, but the FDA categorizes it as Pregnancy Category C. Breastfeeding is not recommended due to potential transfer of monoclonal antibodies into milk. Patients should consult their provider before conception.

Q: Can patients switch from Skyrizi to a biosimilar if it becomes available?

A: Biosimilars for Skyrizi are not expected before 2033, but if they emerge, switching would require clinical assessment. Abrupt discontinuation can lead to disease flare-ups, so tapering or monitoring may be necessary. Always follow provider guidance to avoid rebound inflammation.

Q: How does Skyrizi’s cost compare to other biologics?

A: In the U.S., Skyrizi’s list price (~$7,000/month) is comparable to other IL-23 inhibitors (e.g., Tremfya) but higher than TNF inhibitors (e.g., Humira, now generic). However, its superior efficacy may reduce concomitant therapy costs. Insurance coverage varies; some payers require prior authorization or step therapy.

Q: Are there any dietary or lifestyle restrictions while on Skyrizi?

A: No specific dietary restrictions apply, but patients should maintain a balanced diet to support overall health. Alcohol may increase infection risk, and smoking can worsen psoriasis or Crohn’s symptoms. Regular exercise and stress management also complement therapy.

Q: What should I do if Skyrizi stops working after initial improvement?

A: Loss of efficacy can occur due to antibody formation (rare with Skyrizi) or disease progression. Consult your provider to assess alternatives, such as switching to a different IL-23 inhibitor (e.g., guselkumab) or exploring combination therapy. Never stop treatment abruptly without medical guidance.

Q: How is Skyrizi administered, and can patients self-inject?

A: Skyrizi is administered via pre-filled syringe or autoinjector every 12 weeks (after 3 initial doses at weeks 0, 4, and 8). Most patients are trained to self-inject at home, though healthcare providers can administer it in clinical settings. Proper injection technique is critical to avoid skin reactions.

Q: Does Skyrizi interact with other medications, including vaccines?

A: Live vaccines (e.g., shingles, yellow fever) should be avoided while on Skyrizi due to immune suppression. Inactivated vaccines (e.g., flu) are generally safe. Drug interactions are minimal, but inform your provider about all medications, including OTC drugs and supplements, to avoid potential conflicts.

Leave a Comment

Comments are moderated before appearing. The data you submit is processed according to the Privacy Policy of Bevvy.